ESR1 and neoplasm: R848-TSL administered locally or systemically in combination with ultrasound-mediated hyperthermia resulted in tumor regression and enhanced survival when combined with αPD-1 in mice bearing neu deletion line (NDL) breast tumors (Her2+, ER/PR negative) (113).